INOTREM
24.3.2021 08:02:09 CET | Business Wire | Press release
Inotrem , an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th , 2021. Sven brings an extensive leadership experience in biotech companies’ financial and corporate strategy.
Jean-Jacques Garaud, who co-founded Inotrem and successfully led the company over the last 6 years, will continue to play a key role in the development of the company as Executive VP, Head of Scientific and Medical Affairs.
Prior to joining Inotrem, Sven served as Chief Financial Officer at MetrioPharm, a Swiss biopharmaceutical company. He benefits from a wide-ranging international experience in corporate finance, M&A and private and public fund raisings. He has been involved in several recent exits such as Novimmune’s asset sale to Swedish Orphan Biovitrum, Auris Medical’s IPO on Nasdaq as well as the acquisition of PregLem by Gedeon Richter. Prior to this, Sven worked for UBS Investment Bank and holds a PhD in molecular biology from the University of Zurich.
“We are excited that Sven is coming onboard. He brings a broad set of experiences in the development of advanced clinical biotech companies. With his successful financial and corporate strategy track record, and his deep understanding of the immunomodulation field, he has the ideal profile to lead Inotrem’s next phase of strategic growth,” says Thierry Hercend, Chairman of the Board of Directors at Inotrem.
“I am delighted to have been given the opportunity to lead Inotrem through its next growth phase. Its concept of immunomodulation targeting the TREM-1 pathway to control unbalanced inflammatory responses is very innovative and allows for potential treatments for many indications. I am also looking forward to work with Jean-Jacques Garaud as a visionary co-founder and Inotrem’s talented team to bring targeted therapeutic solutions to patients with inflammatory diseases, both acute as well as chronic,” says Sven Zimmermann.
“Over the past few years, the team has accomplished a remarkable work. Thanks to its dedication, the company achieved numerous milestones and successfully diversified its portfolio focused on the role of the TREM-1 pathway in innate and also adaptive immunity. Today, Inotrem is in an extremely favorable position as it engages its next stage of growth focusing on product development and making regulatory advances. I look forward to contributing to Inotrem’s continued success” says Jean-Jacques Garaud.
Based in Paris with a Research Center in Nancy, Inotrem today employs 20 people with the support of leading European and North American investors. Its lead product candidate, nangibotide, currently undergoes two Phase II clinical trials. One is the Phase IIb ASTONISH trial in 450 patients with septic shock being performed in 50 clinical sites in Europe and the US. The second Phase II trial with nangibotide targets the severe forms of COVID-19 in initially 60 patients in 7 sites globally. The latter was declared “National Priority Research” by the French government. In addition, Inotrem is also developing an antibody program for chronic inflammatory diseases and immuno-oncology applications. Moreover, the company has secured a strategic licensing agreement with Roche Diagnostic for a companion diagnostics test to stratify septic shock patients. Inotrem was recently chosen for the second year in a row, to join the French Tech 120, a government program dedicated to support the development of fast-growing startups.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
For more information please visit: www.inotrem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005049/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Launches Multi-Orbit Satellite Connectivity on Mexico’s Viva1.6.2026 20:00:00 CEST | Press release
SES, a leading space solutions company, and Viva, Mexico’s ultra low-cost airline, launched fast and reliable multi-orbit satellite inflight connectivity service on Viva’s Airbus aircraft, strengthening SES’s position as a leading provider of satellite-powered broadband inflight service in the Americas and around the world. “Viva’s passengers will soon benefit from reliable, multi-orbit satellite connectivity that will provide the same fast and dependable internet access they enjoy at home no matter where or when they fly. SES’ partnerships with growing airlines like Viva highlight how carriers throughout the Americas are leading the way when it comes to the most advanced connectivity. SES is the engine that powers inflight connectivity, a trusted partner that makes airline operations easier,” said Mike DeMarco, SES President of Mobility. A total of 60 A320s and 40 A321s are set to offer the SES solution in the coming years. With the youngest Latin American fleet of Airbus A320s and A3
Motive Powers Latin America’s Next Wave of Mobile Innovation1.6.2026 17:00:00 CEST | Press release
Motive Entitlement Server enabling satellite connectivity in the Andes to fraud-free authentication in Brazil Motive, a global leader in entitlement and connected device & service management, joined operators and industry leaders at M360 LATAM in Mexico City, showcasing live deployments across the region's most consequential use cases: Satellite Direct-to-Device connectivity for unreachable geographies, end-to-end eSIM provisioning and visibility at scale, and SIM-based silent authentication replacing fraud-exposed SMS OTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260531906729/en/ Across landmark deployments with multiple Claro, Vivo, and Entel operations, Motive’s Entitlement Server (Motive ES) has moved from infrastructure component to regional growth engine. These deployments are citing measurable commercial growth, enabling streamlined eSIM provisioning, improved device onboarding experiences, and new revenue oppor
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 16:00:00 CEST | Press release
Clients Can Research Stocks, Analyze Performance, and Generate Trade Instructions in Claude. The Client Approves Every Trade. Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analy
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom